FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021908906> ?p ?o ?g. }

• W3021908906 abstract "Abstract Introduction Factors influencing development and course of ophthalmopathy, the most common extrathyroidal manifestation of Graves’ disease, remain poorly defined. Clinical Case A 46 year old healthy, non-smoking, medical secretary, presented with Graves’ disease. Laboratory investigation showed thyrotoxicosis with high thyroid stimulation immunoglobulin (TSI) levels (1608 %, normal &lt;140%). At presentation there was no evidence of thyroid eye disease on clinical exam and orbital MRI. Treatment with Methimazol and PTU induced severe pruritus and she underwent total thyroidectomy. One month after surgery she presented with retroorbital pain, eyelid edema and chemosis, as well as bilateral limitation in abduction; a clinical activity score (CAS) of 3/7. She received IV pulse methylprednisolone 4.5 gr with minor improvement. MRI showed bilateral thickening of all rectus muscles with orbital fat infiltration. TSI increased concomitantly to 3600%. Three months later, she underwent standard retrobulbar radiotherapy (20 Gy), again with only minor improvement. She continued treatment with oral prednisone 20mg with small fluctuations in disease activity in the following months during which TSI remained high (3145%) and latent tuberculosis was detected (elevated interferon-gamma release assay). Therefore, rifampicin 600mg/d was started. A month later the ophthalmopathy worsened (a CAS score of 5/7 without optic neuropathy). Laboratory tests showed new perturbation in thyroid function tests (TSH increased from 5 to 15 mIU/l, normal: 0.5-5; FT4 decreased from 16 to 11 pmol/l, normal: 10-20) and TSI increased to 3879%. Euthyrox dose was increased by 50% from 800 to 1200 microgram/week. It was postulated that prednisone was also being rapidly metabolized by rifampicin mediated induction of the CYP450, and therefore the dose was increased from 20 to 40 mg/d. Six weeks later, normalization of thyroid function tests was followed by improvement in the ophthalmopathy (CAS-3). Conclusion (Clinical lesson) A) De-novo severe Graves’ ophthalmopathy after thyroidectomy requiring multiple forms of treatment is rare but close surveillance is advisable, perhaps particularly in the presence of high TSI. A plausible mechanism may be transient increase in antigenic exposure/dissemination during surgery. B) Rifampicin, through induction of cytochrome P450-mediated metabolism of levothyroxine, steroids and mycophenolate (the latter not used in our patient) can lead to disease flare-up. Tight clinical and laboratory monitoring of thyroid function tests with individualized dose escalation might be needed. In the future, pharmacogenomics may serve to personalize treatment protocols." @default.
• W3021908906 created "2020-05-13" @default.
• W3021908906 creator A5014768909 @default.
• W3021908906 creator A5027092637 @default.
• W3021908906 creator A5039010087 @default.
• W3021908906 creator A5042599481 @default.
• W3021908906 creator A5088392978 @default.
• W3021908906 date "2020-04-01" @default.
• W3021908906 modified "2023-10-18" @default.
• W3021908906 title "SUN-LB87 De-Novo Graves Ophthalmopathy After Total Thyroidectomy With Exacerbation Following Rifampicin Therapy for Latent Tuberculosis: A Call for Attention to Disease Modifying Interventions" @default.
• W3021908906 doi "https://doi.org/10.1210/jendso/bvaa046.2230" @default.
• W3021908906 hasPublicationYear "2020" @default.
• W3021908906 type Work @default.
• W3021908906 sameAs 3021908906 @default.
• W3021908906 citedByCount "0" @default.
• W3021908906 crossrefType "journal-article" @default.
• W3021908906 hasAuthorship W3021908906A5014768909 @default.
• W3021908906 hasAuthorship W3021908906A5027092637 @default.
• W3021908906 hasAuthorship W3021908906A5039010087 @default.
• W3021908906 hasAuthorship W3021908906A5042599481 @default.
• W3021908906 hasAuthorship W3021908906A5088392978 @default.
• W3021908906 hasBestOaLocation W30219089061 @default.
• W3021908906 hasConcept C126322002 @default.
• W3021908906 hasConcept C141071460 @default.
• W3021908906 hasConcept C2776652619 @default.
• W3021908906 hasConcept C2778720950 @default.
• W3021908906 hasConcept C2778840127 @default.
• W3021908906 hasConcept C2779714575 @default.
• W3021908906 hasConcept C526584372 @default.
• W3021908906 hasConcept C71924100 @default.
• W3021908906 hasConcept C90924648 @default.
• W3021908906 hasConceptScore W3021908906C126322002 @default.
• W3021908906 hasConceptScore W3021908906C141071460 @default.
• W3021908906 hasConceptScore W3021908906C2776652619 @default.
• W3021908906 hasConceptScore W3021908906C2778720950 @default.
• W3021908906 hasConceptScore W3021908906C2778840127 @default.
• W3021908906 hasConceptScore W3021908906C2779714575 @default.
• W3021908906 hasConceptScore W3021908906C526584372 @default.
• W3021908906 hasConceptScore W3021908906C71924100 @default.
• W3021908906 hasConceptScore W3021908906C90924648 @default.
• W3021908906 hasLocation W30219089061 @default.
• W3021908906 hasLocation W30219089062 @default.
• W3021908906 hasOpenAccess W3021908906 @default.
• W3021908906 hasPrimaryLocation W30219089061 @default.
• W3021908906 hasRelatedWork W13777425 @default.
• W3021908906 hasRelatedWork W13925909 @default.
• W3021908906 hasRelatedWork W18282461 @default.
• W3021908906 hasRelatedWork W19537637 @default.
• W3021908906 hasRelatedWork W5516346 @default.
• W3021908906 hasRelatedWork W6329575 @default.
• W3021908906 hasRelatedWork W924460 @default.
• W3021908906 hasRelatedWork W9801543 @default.
• W3021908906 hasRelatedWork W17846074 @default.
• W3021908906 hasRelatedWork W21060900 @default.
• W3021908906 isParatext "false" @default.
• W3021908906 isRetracted "false" @default.
• W3021908906 magId "3021908906" @default.
• W3021908906 workType "article" @default.